Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC8 | Q09428 | 12/20 | 0.44 |
| ▸ | KCNJ11 | Q14654 | 12/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.31 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4266838 | 0.89 | ABCC8 (0.43) | ABCC8KCNJ11GRIA1GRIA2GRIA3 | |
| SCHEMBL4254891 | 0.83 | ABCC8 (0.42) | ABCC8KCNJ11GRIA1GRIA2GRIA3 | |
| SCHEMBL7565061 | 0.82 | ABCC8 (0.43) | ABCC8KCNJ11GRIA1GRIA2GRIA3 | |
| SCHEMBL8491945 | 0.80 | ABCC8 (0.46) | ABCC8KCNJ11GRIA1GRIA2GRIA3 | |
| SCHEMBL7563303 | 0.79 | TAAR1 (0.41) | ABCC8KCNJ11TAAR1 | |
| SCHEMBL4261624 | 0.78 | ABCC8 (0.45) | ABCC8KCNJ11GRIA1GRIA2GRIA3 | |
| SCHEMBL4260978 | 0.74 | ABCC8 (0.43) | ABCC8KCNJ11 | |
| SCHEMBL8286612 | 0.74 | ABCC8 (0.50) | ABCC8KCNJ11GRIA1GRIA2GRIA3 | |
| SCHEMBL7077604 | 0.74 | ABCC8 (0.44) | ABCC8KCNJ11GRIA1GRIA2GRIA3 | |
| SCHEMBL6792625 | 0.74 | ABCC8 (0.44) | ABCC8KCNJ11GRIA1GRIA2GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | DARA BIOSCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | DARA BIOSCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| WO-1999032494-A1 | FUSED 1,2,4-THIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | PYGB, PC, KCNN3 | ABCC8 415/4885KCNJ11 18/4885GRIA1 1265/4885 |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | PC, LIPE, ATP5ME | ABCC8 605/4885KCNJ11 24/4885GRIA1 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.